Lineage Cell Therapeutics, Inc. (AMEX: LCTX) last traded at $0.979, down 0.92% on the session. The quote above updates while this page is open; the figures below are drawn from Lineage Cell Therapeutics, Inc.’s own filings and are restated only when a new one is published.
Lineage Cell Therapeutics, Inc. trades on AMEX under the ticker LCTX. Its market capitalisation is $247.50 million.
Valuation measures for Lineage Cell Therapeutics, Inc., derived from the latest quote and its most recent SEC filing.
| Market cap | $247.50M |
|---|---|
| Enterprise value | $256.56M |
| Price / sales | 18.92 |
| Price / book | 4.06 |
| Beta | 1.27 |
Trailing-twelve-month figures tagged in Lineage Cell Therapeutics, Inc.'s XBRL filings with the SEC.
| Revenue (TTM) | $13.08M |
|---|---|
| Net income (TTM) | -$32.26M |
| Operating margin | -205.23% |
| Return on equity | -52.96% |
| Cash | $37.35M |
Range and volume for LCTX over the past 52 weeks.
| 52-week high | $2.09 |
|---|---|
| 52-week low | $0.880 |
| Volume | 30.2K |
| Average volume | 1.15M |
| Previous close | $0.988 |
Invest a chosen dollar amount in Lineage Cell Therapeutics, Inc. with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell LCTX.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.